UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): September 8, 2010
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
During
September 2010, Entera Bio Ltd. ("Entera"), a 50% subsidiary of our wholly owned
subsidiary Oramed Ltd., is making presentations at investors' conferences of its
shareholder D.N.A. Biomedical Solutions Ltd.
A copy of
the presentation material is attached to this Current Report on Form 8-K as
Exhibit 99.1 and is incorporated herein by reference.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
99.1
|
Entera
presentation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
|||
|
Dated:
September 8, 2010
|
|||
|
By:
|
/s/
Nadav Kidron
|
||
|
Nadav
Kidron
|
|||
|
President,
CEO and Director
|
|||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|||||
|
99.1
|
Entera
presentation
|
|||||
This
presentation may contain forward-looking statements, including statements
regarding the intent, belief or current expectations of Oramed Pharmaceuticals
Inc. and affiliates about the market, business, properties, financial condition
and results of operations of our 50% indirectly held subsidiary, Entera Bio Ltd.
Words such as “believe,” “expect,” “intend,” “estimate,” "target," "goal,"
variations of such words and similar expressions are intended to identify
forward-looking statements but are not the exclusive means of identifying such
statements. Actual results may differ materially from those projected, expressed
or implied in the forward-looking statements as a result of various factors
including, without limitation, the factors set forth in our filings with the
Securities and Exchange Commission including, without limitation, Item 1.A of
our annual report on Form 10-K for the fiscal year ended December 31, 2009,
under the caption “Risk Factors.” Any forward-looking statements contained
herein speak only as of the date hereof, and we caution existing and prospective
investors not to place undue reliance on such statements. Such forward-looking
statements do not purport to be predictions of future events or circumstances,
and therefore, there can be no assurance that any forward-looking statement
contained our releases will prove to be accurate. We undertake no obligation to
update or revise any forward-looking statements. All subsequent written or oral
forward-looking statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by the cautionary statements set forth
in our filings with the Securities and Exchange Commission including, without
limitation, Item 1.A of our annual report on Form 10-A for the fiscal year ended
December 31, 2009, under the caption “Risk Factors.”
The
material herein is proprietary to Oramed Pharmaceuticals Inc. and any
unauthorized reproduction of any part thereof is strictly
prohibited.
Nothing
herein constitutes an offer to purchase or solicitation to sell securities of
Oramed Pharmaceuticals Inc. or of Entera Bio Ltd.